文献速递肾小球疾病

膜性肾病新进展:将新抗原发现融入临床实践

What's New in Membranous Nephropathy and How to Incorporate New Antigen Discoveries Into Clinical Practice: A Review.
PubMed 文献 · Am J Kidney Dis · 2025-10-17

膜性肾病是成人肾病综合征常见病因,激光显微切割/质谱已发现多个靶抗原,使分类从原发性/继发性转向基于靶抗原的分类。每个靶抗原对应特定临床特征和相关疾病,识别靶抗原有助于寻找病因并指导靶向检查;治疗上风险分层更标准,中高危患者一线使用抗CD20药物,抗浆细胞、抗补体和CAR-T等疗法正在试验中。

要点

  • 激光显微切割/质谱可一次性检测所有靶抗原,是最敏感方法。
  • 膜性肾病分类已转向基于靶抗原,各抗原对应特定临床特征和相关疾病。
  • 中高危进展风险患者一线使用抗CD20药物,抗浆细胞、抗补体和CAR-T疗法在研。

核心结论

  • 膜性肾病分类已从原发性/继发性转向基于靶抗原的分类,识别靶抗原有助于寻找潜在病因并实现靶向检查。
  • 中高危进展风险患者的一线治疗已转向抗CD20药物,抗浆细胞、抗补体和CAR-T等疗法正在临床试验中。

研究设计与样本

  • 本文为综述,总结膜性肾病靶抗原发现及临床实践整合的最新进展。
  • 靶抗原通过激光显微切割/质谱方法发现,该技术可一次性检测所有靶抗原。

主要发现

  • 膜性肾病是成人肾病综合征最常见病因之一,可与恶性肿瘤、药物、感染或自身免疫病相关。
  • 每个靶抗原具有特定临床特征和已知相关疾病,识别靶抗原可帮助进一步确定潜在病因。
  • 治疗进展包括更标准的风险分层,以及中高危进展风险患者一线使用抗CD20药物。
  • 抗浆细胞、抗补体和CAR-T疗法正在试验中。

关键数值与推荐

  • 激光显微切割/质谱是检测靶抗原最敏感的方法,可一次性检测所有靶抗原。
  • 中高危进展风险患者一线使用抗CD20药物。

临床怎么用

  • 临床可基于靶抗原对膜性肾病分类,并据此靶向筛查相关疾病。
  • 对中高危进展风险患者,可考虑抗CD20药物作为一线治疗。

局限性

  • 本文为综述,未报告原始研究样本量、效应值或置信区间等数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Membranous nephropathy (MN) is one of the most common causes of nephrotic syndrome in adults and can be seen in association with other diseases, including malignancy, drugs, infections, or autoimmune diseases. Over the last decade, great progress has been made in understanding the pathogenesis of the disease, resulting from the discovery of several target antigens by use of laser microdissection/mass spectrometry methodology. This technique has proven to be the most sensitive method available and has the advantage of testing for all the target antigens at one time. The discovery of these target antigens has now shifted the classification of MN from primary versus secondary to classification based on the target antigen identified. Each target antigen has its own specific clinical characteristics and known associated diseases. Identification of the target antigen can help further identify the underlying cause for a more targeted approach in looking for associated diseases. Progress has also been made in the treatment of patients with MN, with more standard risk stratification of the patients and a shift in using anti-CD20 drugs as the first line for those with moderate and high risk of progression. Trials are ongoing to further investigate the role of anti-plasma cell, anticomplement, and CAR-T (chimeric antigen receptor T-cell) therapies.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Zand L, Fervenza FC, Sethi S, et al. What's New in Membranous Nephropathy and How to Incorporate New Antigen Discoveries Into Clinical Practice: A Review. Am J Kidney Dis. 2025. PMID: 41110629. doi:10.1053/j.ajkd.2025.08.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。